Compare Divis Laboratories with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs AUROBINDO PHARMA - Comparison Results

DIVIS LABORATORIES     Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES AUROBINDO PHARMA DIVIS LABORATORIES/
AUROBINDO PHARMA
 
P/E (TTM) x 59.2 19.4 304.7% View Chart
P/BV x 13.6 4.2 324.5% View Chart
Dividend Yield % 0.4 0.3 178.9%  

Financials

 DIVIS LABORATORIES   AUROBINDO PHARMA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-19
AUROBINDO PHARMA
Mar-19
DIVIS LABORATORIES/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,639830 197.5%   
Low Rs1,115527 211.5%   
Sales per share (Unadj.) Rs186.3333.9 55.8%  
Earnings per share (Unadj.) Rs51.040.4 126.3%  
Cash flow per share (Unadj.) Rs57.351.8 110.7%  
Dividends per share (Unadj.) Rs16.002.50 640.0%  
Dividend yield (eoy) %1.20.4 315.3%  
Book value per share (Unadj.) Rs261.8237.1 110.4%  
Shares outstanding (eoy) m265.47585.91 45.3%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x7.42.0 363.7%   
Avg P/E ratio x27.016.8 160.7%  
P/CF ratio (eoy) x24.013.1 183.3%  
Price / Book Value ratio x5.32.9 183.8%  
Dividend payout %31.46.2 506.9%   
Avg Mkt Cap Rs m365,592397,569 92.0%   
No. of employees `00011.817.9 66.4%   
Total wages/salary Rs m5,42325,849 21.0%   
Avg. sales/employee Rs Th4,175.110,956.9 38.1%   
Avg. wages/employee Rs Th457.71,447.7 31.6%   
Avg. net profit/employee Rs Th1,141.81,324.3 86.2%   
INCOME DATA
Net Sales Rs m49,463195,636 25.3%  
Other income Rs m1,5561,553 100.2%   
Total revenues Rs m51,019197,189 25.9%   
Gross profit Rs m18,71839,519 47.4%  
Depreciation Rs m1,6896,680 25.3%   
Interest Rs m352,626 1.3%   
Profit before tax Rs m18,55131,767 58.4%   
Minority Interest Rs m027 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-881 0.0%   
Tax Rs m5,0237,269 69.1%   
Profit after tax Rs m13,52723,645 57.2%  
Gross profit margin %37.820.2 187.3%  
Effective tax rate %27.122.9 118.3%   
Net profit margin %27.312.1 226.3%  
BALANCE SHEET DATA
Current assets Rs m46,501153,645 30.3%   
Current liabilities Rs m8,468120,429 7.0%   
Net working cap to sales %76.917.0 452.9%  
Current ratio x5.51.3 430.4%  
Inventory Days Days131135 96.7%  
Debtors Days Days8664 134.8%  
Net fixed assets Rs m25,797103,909 24.8%   
Share capital Rs m531586 90.6%   
"Free" reserves Rs m68,962138,322 49.9%   
Net worth Rs m69,493138,908 50.0%   
Long term debt Rs m01,800 0.0%   
Total assets Rs m80,383264,544 30.4%  
Interest coverage x531.013.1 4,054.5%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.60.7 83.2%   
Return on assets %16.99.9 169.9%  
Return on equity %19.517.0 114.4%  
Return on capital %26.723.8 112.2%  
Exports to sales %049.6 0.0%   
Imports to sales %24.618.8 131.2%   
Exports (fob) Rs mNA97,091 0.0%   
Imports (cif) Rs m12,18736,741 33.2%   
Fx inflow Rs m41,23897,316 42.4%   
Fx outflow Rs m12,40540,589 30.6%   
Net fx Rs m28,83356,727 50.8%   
CASH FLOW
From Operations Rs m9,54316,220 58.8%  
From Investments Rs m-6,854-28,768 23.8%  
From Financial Activity Rs m-2,45919,191 -12.8%  
Net Cashflow Rs m2306,656 3.4%  

Share Holding

Indian Promoters % 52.0 54.1 96.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 8.0 148.4%  
FIIs % 19.0 27.7 68.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 10.2 168.6%  
Shareholders   31,796 69,601 45.7%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   NOVARTIS  ASTRAZENECA PHARMA  DISHMAN PHARMA  IPCA LABS  JUBILANT LIFE SCIENCES  

Compare DIVIS LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Tanks 531 Points; Reliance Industries & IndusInd Bank Fall 5%(Closing)

Indian share markets witnessed huge selling pressure today and failed to hold on to their opening gains as profit booking and weakness across all sectors erased gains.

Related Views on News

J.B.CHEMICALS Share Price Up by 7%; BSE HEALTHCARE Index Up 1.0% (Market Updates)

Jan 25, 2021 | Updated on Jan 25, 2021

J.B.CHEMICALS share price is trading up by 7% and its current market price is Rs 1,066. The BSE HEALTHCARE is up by 1.0%. The top gainers in the BSE HEALTHCARE Index are J.B.CHEMICALS (up 7.2%) and AUROBINDO PHARMA (up 8.0%). The top losers are DR. LAL PATHLABS (down 0.2%) and CAPLIN POINT (down 0.3%).

AUROBINDO PHARMA Share Price Up by 10%; BSE HEALTHCARE Index Up 1.4% (Market Updates)

Jan 25, 2021 | Updated on Jan 25, 2021

AUROBINDO PHARMA share price is trading up by 10% and its current market price is Rs 1,021. The BSE HEALTHCARE is up by 1.4%. The top gainers in the BSE HEALTHCARE Index is AUROBINDO PHARMA (up 10.3%). The top losers are NATCO PHARMA (down 0.3%) and ERIS LIFESCIENCES (down 0.4%).

CIPLA Share Price Up by 5%; BSE HEALTHCARE Index Up 1.2% (Market Updates)

Jan 25, 2021 | Updated on Jan 25, 2021

CIPLA share price is trading up by 5% and its current market price is Rs 850. The BSE HEALTHCARE is up by 1.2%. The top gainers in the BSE HEALTHCARE Index are CIPLA (up 5.0%) and AUROBINDO PHARMA (up 9.6%). The top losers are NATCO PHARMA (down 0.2%) and PIRAMAL ENTERPRISES (down 0.6%).

AUROBINDO PHARMA at All Time High; BSE HEALTHCARE Index Up 1.0% (Market Updates)

Jan 25, 2021 | Updated on Jan 25, 2021

AUROBINDO PHARMA share price has hit an all time high at Rs 1,012 (up 9.4%). The BSE HEALTHCARE Index is up by 1.0%. Among the top gainers in the BSE HEALTHCARE Index today are AUROBINDO PHARMA (up 9.4%) and ABBOTT INDIA (up 0.8%). The top losers include THYROCARE TECHNOLOGIES (down 0.1%) and LAURUS LABS (down 0.2%).

LAURUS LABS at 52 Week High; BSE 500 Index Down 0.2% (Market Updates)

Jan 25, 2021 | Updated on Jan 25, 2021

LAURUS LABS share price has hit a 52-week high. It is presently trading at Rs 381. BSE 500 Index is down by 0.2% at 19,022. Within the BSE 500, LAURUS LABS (up 2.5%) and GATEWAY DISTRIPARKS (up 12.4%) are among the top gainers, while top losers are VODAFONE IDEA and APOLLO TYRES.

More Views on News

Most Popular

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

Buzzing Sectors Before Budget 2021(Fast Profits Daily)

Jan 12, 2021

The budget is just a few weeks away. Which stocks can you expect to move? Find out in this video.

Here's Why Smallcaps Could Be Your Best Investment in 2021(Profit Hunter)

Jan 12, 2021

Select smallcaps hold a great potential to become the multibaggers of tomorrow. Here's how you could get in early into these stocks.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Jan 25, 2021 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 5-YR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS